FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation discusses natural DHT blockers like rice bran oil, which may reduce 5α-reductase activity similarly to Minoxidil and Dutasteride. One user argues that finasteride is more reliable and effective than natural alternatives.
The user shared a 3-month progress update on hair loss treatment using finasteride (1 mg), minoxidil (5% once or twice daily), and microneedling (1.5mm every 2 weeks) with no side effects. Commenters are impressed, discussing hair follicle revival and the user's method, noting the hair appears darker.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.